The study focuses on patients with Marginal Zone Lymphoma (MZL), a type of blood cancer that affects specific areas of the lymphatic system. The research will test a medication called obinutuzumab (Gazyvaro), which is given through an intravenous infusion directly into the bloodstream.
The purpose of this research is to evaluate how well obinutuzumab works and what side effects it may cause when used as a first treatment for people with MZL who cannot receive local treatments or for whom local treatments have not worked. The medication will be given as a single treatment, meaning it will not be combined with other cancer medications.
During the study, participants will receive obinutuzumab through an intravenous infusion at a dose of 1,000 mg. The treatment period may last up to 30 months. Throughout the study, doctors will monitor the participants’ response to treatment and track any side effects that may occur. The study will also look at how the treatment affects participants’ quality of life and whether any other health conditions develop over time.
Germany 
